Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
TEST:
ThyGeNEXT® + ThyraMIR®
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Interpace Biosci
Type:
Laboratory Developed Test
Related tests:
‹
PancraGEN®
PancraGEN®
›
Details
Evidence
News
ThyGeNEXT® + ThyraMIR®v2 provides mutational analysis, microRNA algorithmic classification, and microRNA pairwise expression profiling. The test analyzes microRNA signatures to improve risk assessment of indeterminate thyroid nodules.
Cancer:
Thyroid Gland Carcinoma, Thyroid Gland Papillary Carcinoma
Gene:
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), GNAS (GNAS Complex Locus), HRAS (Harvey rat sarcoma viral oncogene homolog), KRAS (KRAS proto-oncogene GTPase), NRAS (Neuroblastoma RAS viral oncogene homolog)
See More ...
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), GNAS (GNAS Complex Locus), HRAS (Harvey rat sarcoma viral oncogene homolog), KRAS (KRAS proto-oncogene GTPase), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK (Neurotrophic receptor tyrosine kinase), PAX8 (Paired box 8), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PPARG (Peroxisome Proliferator Activated Receptor Gamma), PTEN (Phosphatase and tensin homolog), RET (Ret Proto-Oncogene), TERT (Telomerase Reverse Transcriptase)
Method:
Next-Generation Sequencing (NGS)
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.